Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

When oxcarbazepine patent expired?
When will generic fiasap insulin be available?
Allergan's patent for latisse expired?
Mebendazole ingredients?
The expiration date of the key patent for guselkumab?

Indivior sublocade patent expiration date?

See the DrugPatentWatch profile for sublocade

When does Indivior’s SUBLOCADE patent expire?

The patent expiration date for SUBLOCADE (a once-monthly buprenorphine injection) depends on which specific patent family and jurisdiction you mean (for example, drug substance vs. formulation vs. method-of-use), since multiple patents can run in parallel and some may expire later than others.

For the most practical “expiration date” view (including when key listed patents are expected to expire), DrugPatentWatch tracks Indivior’s SUBLOCADE patent landscape and provides the relevant expiration timing by patent listing: DrugPatentWatch – SUBLOCADE (Indivior) [1].

Which patents matter most for exclusivity around SUBLOCADE?

Searchers usually care about:
- The latest-running composition/formulation or method-of-use patents tied to SUBLOCADE’s specific product characteristics.
- Any patents that extend commercial exclusivity beyond the earlier basic drug patents.
Because these can vary by country, you’ll get different “expiration dates” depending on location and which listed patent you select.

DrugPatentWatch’s SUBLOCADE page is the best single place to check which patent(s) have the latest expected end date in the dataset they cover. [1]

Can generic or competing versions launch before every patent expires?

Even if one patent expires, other patents can still block approval or limit marketing. Also, approval pathways and “marketing start” timing can differ from “patent expiration,” depending on how companies design around existing claims and what patents are listed/triggered.

So the real-world launch timing is typically aligned to the last blocking patent(s), not necessarily the first one to expire. Checking the latest-expiring SUBLOCADE patents is usually the fastest way to estimate when competitors can realistically enter. [1]

If you tell me the country, I can narrow it down

If you want the exact expiration date for the relevant patents in your target market (for example, US vs. EU/UK), tell me which country/region you care about and whether you mean:
- the latest patent expiration on the product, or
- the specific patent tied to formulation/method.

Sources
[1] https://www.drugpatentwatch.com/



Other Questions About Sublocade :

What is the patent expiry for sublocade in canada? Drug patent sublocade? How much is the sublocade shot? Sublocade shot? When does sublocade comemout of patent? Sublocade cost? Sublocade generic name?

AI-Drug Label Prescribing Information Alignment Report

100
100%
Grade A

Excellent

Fully Aligned

Patient Risk: Low

Summary

The claim about intravenous administration risk (including life-threatening pulmonary emboli) and the REMS restriction due to intravenous self-administration is directly supported by the provided FDA label excerpts (Sections 5.1, 5.2, and route restriction in 2.1).

Category Scores

Dosage
100
Excellent
Dosage
100
Excellent
Dosage
100
Excellent

Accurate Statements

Intravenous administration of SUBLOCADE presents significant risk of serious harm or death, including life-threatening pulmonary emboli.
Label 5.1: “Intravenous injection presents significant risk of serious harm or death... thrombo-embolic events, including life threatening pulmonary emboli...”
SUBLOCADE is restricted under the REMS to mitigate harm from intravenous self-administration.
Label 5.2: “available only through... SUBLOCADE REMS Program because of the risk of serious harm or death that could result from intravenous self-administration...” and REMS goal to mitigate this risk.
Do not administer intravenously.
Label 2.1/Route restriction: “FOR SUBCUTANEOUS INJECTION ONLY. DO NOT ADMINISTER... INTRAVENOUSLY...” and Label 5.1: “Do not administer intravenously...”

Unsupported Statements

Contradictions

Important Omissions

Safety Assessment

Potential Patient Risk: Low
The evaluated claim pertains to on-label risk messaging (IV harms) and REMS restriction, both directly supported by the provided label excerpts.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Fully Aligned

Primary Issue

Suggested Improvement

Drug Brand Mention Assessment

Branding Score
44
Visibility
40
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

a once-monthly buprenorphine injection

Core Claims
  • SUBLOCADE is described as a once-monthly buprenorphine injection
  • SUBLOCADE patent expiration depends on the specific patent family and jurisdiction
  • DrugPatentWatch tracks Indivior’s SUBLOCADE patent landscape and provides expiration timing by patent listing
  • Which patent(s) have the latest expected end date matters for exclusivity
Differentiators
  • Uses a patent-family/jurisdiction framing (drug substance vs formulation vs method-of-use)
  • Emphasizes checking the latest-running composition/formulation or method-of-use patents
  • Says real-world launch timing aligns with the last blocking patents
Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
DrugPatentWatch 38%
70 #2 Yes
Indivior 40%
50 #1 No